Mutations in HRR genes such as ATM, CHEK2, RAD51, CHEK2 and PALB2 lead to homologous recombination deficiency (HRD) in HGSC and offer a druggable target. Here, CHEK2 is linked to hypoparathyroidism-retardation-dysmorphism syndrome.